Despite the rollout of Lenacapavir, a highly effective long-acting HIV prevention shot, plans to prioritize certain groups may overlook an important segment of men in South Africa.

The first shipment of Lenacapavir, a groundbreaking long-acting injectable that prevents HIV with just two shots per year, arrived in South Africa from the United States in early April 2026. Clinical trials demonstrated close to 100% efficacy, raising hopes for better management and prevention of the virus among at-risk populations.

However, while plans are underway for a rollout expected to begin in June 2026, the initial focus will be on adolescent girls and young women, pregnant and breastfeeding women, transgender people, sex workers, men who have sex with men, and people who inject drugs. This strategic prioritization aims to address high-risk groups where HIV prevalence is notably higher.

Yet, this approach may inadvertently miss a critical segment of the male population: heterosexual men. According to health experts, these men are often overlooked in prevention strategies due to societal norms that place the onus on women for sexual and reproductive health. As Lenacapavir offers a convenient method with fewer dosing requirements, it could significantly reduce HIV transmission if effectively utilized by all at-risk individuals.

Health officials acknowledge the importance of including heterosexual men in HIV prevention efforts. However, challenges persist due to cultural and social barriers that discourage open discussions about sexual health among men. Additionally, the stigma associated with HIV can prevent men from seeking treatment or participating in clinical trials.

To ensure comprehensive coverage, public health campaigns must address these barriers by promoting awareness and education on the benefits of Lenacapavir for all genders. Engaging community leaders and influencers to normalize conversations around sexual health could help break down these obstacles. Furthermore, providing accessible and confidential healthcare services will be crucial in encouraging men to participate.

In conclusion, while the rollout of Lenacapavir is a significant step forward in HIV prevention, it must include heterosexual men to achieve its full potential. Addressing cultural and social barriers through targeted outreach and education can help ensure that this life-saving technology reaches all those who need it most.